11β Hydroxysteroid dehydrogenase type 1 Gene Expression in Obesity and its Complications

被引:0
作者
Aziz, Hend A. [1 ]
Raslan, Mai [1 ]
El Dahshan, Dina [2 ]
Afify, Mie [3 ]
Hamimy, W. I. [4 ]
Gouda, Weaam [3 ]
机构
[1] Beni Suef Univ, Fac Postgrad Studies Adv Sci, Biotechnol & Life Sci Dept, Bani Suwayf, Egypt
[2] Beni Suef Univ, Fac Med, Clin Pathol Dept, Bani Suwayf, Egypt
[3] Natl Res Ctr, Biotechnol Res Inst, Biochem Dept, Giza, Egypt
[4] Cairo Univ, Fac Med, Obes Surg Unit, Giza, Egypt
来源
EGYPTIAN JOURNAL OF CHEMISTRY | 2023年 / 66卷 / 07期
关键词
11; beta-HSD1; gene expression; obese; diabetes mellitus; hypertension; ADIPOSE-TISSUE; CORTISOL METABOLISM; GLUCOCORTICOID METABOLISM; INTERNATIONAL-SYMPOSIUM; PIMA-INDIANS; WEIGHT-LOSS; WOMEN; DIFFERENTIATION; POLYMORPHISMS; SENSITIVITY;
D O I
10.21608/EJCHEM.2022.157145.6819
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Background: 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) is an enzyme greatly expressed in the adipose tissue and acts as a reductase (convert inactive cortisone into active cortisol). Previous study assumed that the pathophysiology of obesity might be elaborated by tissue-specific dysregulation of cortisol metabolism. Numerous studies have assessed 11 beta-HSD1 gene polymorphisms and obesity risk. However, there is still a lack in the published literature evaluating the association between 11 beta-HSD1 gene expression and the risk of obesity and its related diseases. Objective: This study was carried out to investigate the relationship of 11 beta-HSD1 gene expression with obesity, diabetes, and hypertension in subcutaneous adipose tissue. Moreover, this study correlates 11 beta-HSD1 gene expression with various parameters in obese patients. Patients and methods: Our study was conducted on 74 subjects; they were selected from kasr Al Aini Hospital, Surgical Department. Obese patients (n=56) with BMI >= 30 kg/m(2) were divided according to obesity complications into obese (n=26), obese hypertensive (n=14) and obese diabetic (n=16) groups beside 18 age- and sex-matched normal weight healthy subjects as control group. The expression of 11 beta-HSD1 was evaluated with real-time PCR. Results: There was a significant difference between obese and controls in HSD11 beta 1 gene expression level and we found a significant difference in obese patients with diabetes and hypertension compared to normal weight healthy controls. Furthermore, the correlation and regression analysis showed that the 11 beta-HSD1 gene expression was correlated with fasting blood glucose and triglycerides levels in obese patients. Conclusion: The study shows a significant association between subcutaneous adipose tissue 11 beta-HSD1 gene expression and obesity. Moreover, the subcutaneous adipose tissue expression level of 11 beta-HSD1 gene was correlated to fasting plasma glucose level and also correlated to triglycerides. So the 11 beta-HSD1 gene expression is significantly increased the risk of diabetes mellitus and hypertension in obese individuals.
引用
收藏
页码:165 / 174
页数:10
相关论文
共 50 条
  • [21] Association between 11β-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in Bosnian population
    Dujic, Tanja
    Bego, Tamer
    Mlinar, Barbara
    Semiz, Sabina
    Malenica, Maja
    Prnjavorac, Besim
    Ostanek, Barbara
    Marc, Janja
    Causevic, Adlija
    BIOCHEMIA MEDICA, 2012, 22 (01) : 76 - 85
  • [22] Inhibition of 11β-hydroxysteroid dehydrogenase type 1 ameliorates obesity-related insulin resistance
    Shao, Shiying
    Zhang, Xiaojie
    Zhang, Muxun
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 478 (01) : 474 - 480
  • [23] BVT.2733, a Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, Attenuates Obesity and Inflammation in Diet-Induced Obese Mice
    Wang, Long
    Liu, Juan
    Zhang, Aisen
    Cheng, Peng
    Zhang, Xiao
    Lv, Shan
    Wu, Lin
    Yu, Jing
    Di, Wenjuan
    Zha, Juanmin
    Kong, Xiaocen
    Qi, Hanmei
    Zhong, Yi
    Ding, Guoxian
    PLOS ONE, 2012, 7 (07):
  • [24] In Vivo Activity of 11β-Hydroxysteroid Dehydrogenase Type 1 in Man: Effects of Prednisolone and Chenodesoxycholic Acid
    Diederich, S.
    Quinkler, M.
    Mai, K.
    Schoeneshoefer, M.
    Baehr, V.
    Pfeiffer, A.
    Oelkers, W.
    Eigendorff, E.
    HORMONE AND METABOLIC RESEARCH, 2011, 43 (01) : 66 - 71
  • [25] Prenatal Programming of Metabolic Syndrome in the Common Marmoset Is Associated With Increased Expression of 11β-Hydroxysteroid Dehydrogenase Type 1
    Nyirenda, Moffat J.
    Carter, Roderick
    Tang, Justin I.
    de Vries, Annick
    Schlumbohm, Christina
    Hillier, Stephen G.
    Streit, Frank
    Oellerich, Michael
    Armstrong, Victor W.
    Fuchs, Eberhard
    Seckl, Jonathan R.
    DIABETES, 2009, 58 (12) : 2873 - 2879
  • [26] Small Molecule 11β- Hydroxysteroid Dehydrogenase Type 1 Inhibitors
    Sun, Daqing
    Wang, Minghan
    Wang, Zhulun
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (12) : 1464 - 1475
  • [27] 11β-Hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome
    Schnackenberg, Christine G.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (03) : 295 - 300
  • [28] 11β-Hydroxysteroid Dehydrogenase Type 1 as a Potential Treatment Target in Cardiovascular Diseases
    Kupczyk, Daria
    Studzinska, Renata
    Kolodziejska, Renata
    Baumgart, Szymon
    Modrzejewska, Martyna
    Wozniak, Alina
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (20)
  • [29] Association of 11β-hydroxysteroid dehydrogenase type 1 gene polymorphisms with serum alanine aminotransferase activity
    Moon, Seong-Su
    Lee, Young-Sil
    Kim, Jung-Guk
    Lee, In-Kyu
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2013, 99 (03) : 343 - 350
  • [30] Lack of association of the 11 beta-hydroxysteroid dehydrogenase type 1 gene 25669dupA polymorphism with obesity and metabolic syndrome
    Kaitozis, Odysseas
    Anousakis-Vlachochristou, Nikolaos
    Chalikias, George
    Synetos, Andreas
    Latsios, George
    Papanas, Nikolaos
    Toutouzas, Konstantinos
    Tousoulis, Dimitris
    Papazoglou, Dimitrios
    HELLENIC JOURNAL OF CARDIOLOGY, 2021, 62 (02) : 164 - 166